PT  - JOURNAL ARTICLE
AU  - Yi Ju
AU  - Wen Shi Lee
AU  - Hannah G Kelly
AU  - Emily H Pilkington
AU  - Kathleen M Wragg
AU  - Kanta Subbarao
AU  - Thi H.O. Nguyen
AU  - Louise C. Rowntree
AU  - Lilith F Allen
AU  - Katherine Bond
AU  - Deborah A Williamson
AU  - Nghia P Truong
AU  - Magdalena Plebanski
AU  - Katherine Kedzierska
AU  - Siddhartha Mahanty
AU  - Frank Caruso
AU  - Adam K Wheatley
AU  - Jennifer A Juno
AU  - Stephen J Kent
TI  - Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine
AID  - 10.1101/2022.01.08.22268953
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.08.22268953
4099  - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268953.short
4100  - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268953.full
AB  - Humans commonly have low level antibodies to poly(ethylene) glycol (PEG) due to environmental exposure. Lipid nanoparticle mRNA vaccines for SARS-CoV-2 contain small amounts of PEG but it is not known if PEG antibodies are enhanced by vaccination and if there are any consequences. We studied plasma from 55 people receiving the Comirnaty (Pfizer-BioNTech) mRNA vaccine for PEG-specific antibodies. Anti-PEG IgG was commonly detected prior to vaccination and was boosted a mean of 1.78-fold (range 0.68 to 16.6) by vaccination. Anti-PEG IgM increased 2.64-fold (0.76 to 12.84) following vaccination. PEG antibodies did not impact the neutralizing antibody response to vaccination. Pre-existing levels of anti-PEG IgM correlated with increased reactogenicity. A rise in PEG antibodies following vaccination was associated with an increase in the association of PEG-based nanoparticles to blood immune cells ex vivo. We conclude that low level PEG-specific antibodies can be modestly boosted by a lipid nanoparticle mRNA-vaccine and that PEG-specific antibodies are associated with higher reactogenicity. The longer-term clinical impact of the increase in PEG-specific antibodies induced by lipid nanoparticle mRNA-vaccines should be monitored.One-Sentence Summary A rise in PEG antibodies following mRNA lipid nanoparticle vaccination was associated with higher reactogenicity and PEG particle–leukocyte interactions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAustralian Medical Research Future Fund grants 2005544; Australian Research Council awards DP210103114 and DP200100231; Australian National Health and Medical Research Council grants 1149990; Australian National Health and Medical Research Council Investigator or Fellowship grants (SJK, KK, JJ, AKW, FC, DAW and THON); RMIT Vice Chancellor Postdoctoral Fellowship (YJ) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects provided written informed consent and the studies were approved by the University of Melbourne human research and ethics committee (approvals 2056689, 21198153983 and 2021-21626-15756-1) and the Royal Melbourne Hospital human research and ethics committee (approvals 6309/MH-2020, 2013.290 and 68355/MH-2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors